The network, and why it exists
For ultra-rare families. Why this surface is a blog and a signal, not a review site.
The Ultra-rare desk works differently from the other two desks at Zebra Reports. The newborn screening desk has reviews of medical formulas and metabolic supplies. The Ehlers-Danlos desk has reviews of braces, splints, and mobility aids. This desk has a magazine and a network surface, and that is the whole product. There are no reviews here. The reason is structural.
What ultra-rare actually means
Ultra-rare describes a condition that affects so few people that traditional drug development math does not work on it. Pharma cannot recover the cost of a clinical program. Insurance has no schedule for it. Academic medical centers see a single case once every several years, if ever.
N-of-1 plus is a category for therapeutic programs designed for a single patient or a very small group around a single variant. Mila Makovec is the foundational case. Her family and her clinicians designed a custom antisense oligonucleotide for a variant only she had. Other families have followed. Some are individual gene therapies. Some are compounded protocols. Some are devices that exist because a parent and an engineer worked it out.
The "plus" matters. Around every n-of-1 case there is usually a small constellation. Other families with the same variant who appear later. Clinicians who treated the index case. Labs that ran the diagnostic work. Manufacturers who made the molecule or the device. The plus is the network you can sometimes find. Often you cannot find it without help.
Why reviews do not fit
A review is a structured judgment of a product used by a population. It needs a product, a population, and enough cases to compare. Ultra-rare cases violate all three. The product is sometimes compounded, sometimes built from scratch. The population is often one. The comparison set does not exist.
Forcing a review structure on these cases gives a false signal. It would tell readers that a product worked for "people like you" when there are no people like you in the dataset. We do not do that.
What the network surface does
The network surface captures two things. The case update, written by the family or the clinical team with the family as the reporter of record. And the help signal. What kind of help would move this case forward right now. Six tags cover the common shapes: clinician, lab, manufacturing, regulatory, funding, peer.
A clinician signal means we are looking for someone who has seen this variant or a near-variant and is willing to consult or to take the patient. A lab signal means we are looking for a research lab with the assay. Manufacturing means we are looking for a CDMO or a compounding pharmacy that can make what the case needs. Regulatory means we are looking for someone who has been through an Investigational New Drug application or a Plausible Mechanism Framework filing for a similar case. Funding means we are looking for grant or philanthropic capital and we want to be findable to people looking. Peer means we are looking for another family with the same variant or a near-variant.
Contact openness is its own field. A family can choose to be visible to readers without giving up contact details. Routing through the Zebra Reports concierge is the default. Direct contact is only an option when the family explicitly chooses it.
Where funding sits
Funding belongs to the family. If a case generates philanthropic interest, the family decides what to do with that interest. Zebra Reports does not collect funds. The Cureledger investor side works with FDA Priority Review Voucher applicants and runs separately.
Why now
The FDA has explicitly authorized a pathway for ultra-rare cases through the Plausible Mechanism Framework. Tools from the AI side are reaching the point where mechanism-driven design is tractable for individual variants. Multimillionaire and billionaire families with rare disease have been doing this work quietly for years and proving it can be done. Most rare disease families do not have that starting capital. The information clearinghouse is for the families without that starting capital.